Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12832721 | 0.84 | TSHR (0.42) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL9918730 | 0.81 | MAOB (0.36) | MAPTSMN1; SMN2L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL127772 | 0.78 | TSHR (0.43) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL9918732 | 0.78 | ALDH1A1 (0.47) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL130676 | 0.76 | TSHR (0.43) | TSHRCRHBPCRHR2SMN1; SMN2L3MBTL1 | |
| SCHEMBL9918734 | 0.73 | TSHR (0.43) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL16415457 | 0.71 | TSHR (0.48) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL16640636 | 0.68 | TSHR (0.43) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL554285 | 0.67 | NOTUM (0.70) | TSHRCRHBPCRHR2MAPTSMN1; SMN2 | |
| SCHEMBL13198428 | 0.66 | SLC1A1 (0.56) | L3MBTL1LMNAKMT2AMEN1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TSHR 2606/4885CRHBP 4254/4885CRHR2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.